Dr Sardjono Utomo, a senior Indonesian doctor, admitted himself to his local hospital in East Java late Tuesday afternoon. In just over 24 hours, as his fellow doctors phoned hospital after hospital in search of a ventilator in Surabaya – Indonesia’s second-largest city and a few hours’ drive away – the doctor and his wife, Sri Martini, would both be dead. The death of Dr Sardjono and his wife from COVID-19 has raised alarm bells in the world’s fourth-most populated nation, where the pandemic has steadily gone from bad to worse and is now putting significant strain on the country’s poorly equipped health system.
A former Trump fundraiser and a prominent lawyer were among the people scrutinized by the Justice Department for their roles in what a judge described as a possible bribery scheme to win a presidential pardon for a convicted felon, lawyers for the men said Thursday. Lawyer Abbe Lowell's attorney and friend Reid Weingarten said his client was never a target or subject in the Justice Department's inquiry, while former fundraiser Elliot Broidy's attorney William Burck said his client was "not under investigation and has not been accused by anyone of any wrongdoing whatsoever." No one has been charged in the investigation, the status of which is unclear.
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 03 Dec 2020. Estimated NAV Euro Shares Sterling Shares Estimated NAV € 25.2432 £ 22.1901 Estimated MTD return 0.16 % -0.12 % Estimated YTD return 10.24 % 7.53 % Estimated ITD return 152.43 % 121.90 % NAV and returns are calculated net of management and performance fees Market information Euro Shares Amsterdam (AEX) London (LSE) Market Close € 19.10 N/A Premium/discount to estimated NAV -24.34 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1,780.00 Premium/discount to estimated NAV N/A -19.78 % Transactions in own securities purchased into treasury Ordinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/A Liquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A BGHL Capital BGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 13,579,704 294,495 Held in treasury 389,000 N/A Shares Issued 13,968,704 294,495 Since the 1st of December 2020, the daily figures take into account the estimated impact of the conversion. Estimated BG Fund NAV Class B Euro Shares (estimated) € 210.8448 The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL. For further information please contact: Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : email@example.com The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities. This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States. You should always bear in mind that: all investment is subject to risk; results in the past are no guarantee of future results; the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice. This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice. Attachment Daily NAV - BgHL
Press Release Nicox Raises €15 million in Private Placement Strengthens financial position in advance of upcoming key value inflection points Two clinical readouts in Q4 2021 – Mont Blanc Phase 3 for NCX 470 and Mississippi Phase 2b for NCX 4251Long-term shareholder HBM Healthcare Investments participated in the financing alongside specialist institutional investors in the U.S. and Europe December 4, 2020 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a financing through a private placement via the issuance of 3,529,565 new ordinary shares with gross proceeds of €15.0 million. The Company was previously financed to complete both the Mont Blanc Phase 3 trial for NCX 470 and the Mississippi Phase 2b trial for NCX 4251. Proceeds from this financing extend the cash runway well beyond these key inflection points. Nicox’s principal shareholder HBM Healthcare Investments (SIX:HBMN), a leading, publicly listed healthcare investment fund was joined by new U.S. and European institutional investors in this financing. Michele Garufi, Chairman and Chief Executive Officer of Nicox, said, “We are very pleased with the continued support from our long-term shareholder and would like to welcome the new specialist investors who participated in this financing. With a cash runway now well beyond the top-line results of two important trials of our lead product candidates, we are in the ideal position to capitalize optimally on the clinical results of both NCX 4251 and NCX 470 that are expected towards the end of next year.” Proceeds from this financing are not planned to be used to make payments on any of the Company's debts, which are expected to be covered by licensing revenue. Cash Position The Nicox Group had cash, cash equivalents and financial instruments of €39.0 million (excluding the proceeds of this financing) on November 30, 2020 and total financial debt of €18.7 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and a €2 million credit agreement with Société Générale and LCL, guaranteed by the French State, and granted in August 2020 in the context of the COVID-19 pandemic. Status of Key Development Programs NCX 470, Nicox’s lead clinical product candidate, a novel second-generation nitric oxide (NO)-donating bimatoprost analog, is being evaluated in the Mont Blanc and Denali Phase 3 clinical trials for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Top-line results from Mont Blanc are currently expected in Q4 2021 and top-line results from Denali in Q4 2022. The Denali trial is being jointly and equally financed by Nicox and Ocumension Therapeutics, our partner for the Chinese, Korean and South East Asian markets. Together Mont Blanc and Denali will support regulatory submissions in the U.S and China. Results from the Dolomites Phase 2 clinical trial in patients with open‑angle glaucoma or ocular hypertension demonstrated statistical superiority of NCX 470 0.065% over the current standard of care, latanoprost 0.005%. Nicox believes the IOP reduction from baseline at the three time points (8 AM, 10 AM and 4 PM) of 7.6 to 9.8 mmHg is the highest IOP reduction ever reported in an eye drop glaucoma clinical trial. The first Phase 3 trial, Mont Blanc, included an initial adaptive dose selection phase to evaluate two doses of NCX 470, 0.065% and 0.1%. Following the completion of the adaptive design portion of Mont Blanc, the 0.1% dose of NCX 470 was selected for evaluation against latanoprost 0.005% in the second part of the Mont Blanc and in the Denali Phase 3 clinical trials. NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystals and our second clinical program. The Mississippi Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis is expected to be initiated later this month with top-line results currently expected in Q4 2021. If successful in meeting the primary endpoint previously agreed with the U.S. Food and Drug Administration (FDA), the Mississippi trial could represent the first of two pivotal trials needed to support the submission of a New Drug Application (NDA) in the U.S. NCX 4251 is the first product candidate developed as a targeted topical treatment of the eyelid margin in patients with acute exacerbations of blepharitis. The Danube Phase 2 demonstrated a statistically significant reduction in the composite score of key signs and symptoms of blepharitis at day 14 and also showed encouraging results in dry eye disease endpoints. We continue to closely watch the spread and impact of the COVID-19 pandemic. Some of the clinical trials indicated above have just started or will start in the near future, and any potential impact of the pandemic on them cannot be fully assessed at this time. We do not currently anticipate major delays in our clinical timelines but we are monitoring the situation and will provide an update when needed. Main terms of the financing The share capital increase without preferential rights, by issuance of 3,529,565 new ordinary shares, was reserved for subscription by French or foreign companies or mutual funds investing in the pharmaceutical biotechnology sector (sociétés ou fonds gestionnaires d’épargne collective de droit français ou de droit étranger investissant dans le secteur pharmaceutique/biotechnologique) pursuant to the 7th resolution of the Extraordinary General Meeting of Nicox dated June 30, 2020. The subscription price of the new shares has been set by the Board of directors on December 4 at €4.25 per new share representing a discount of 14.8% on the Volume Weighted Average Price (VWAP) over the last 3 trading days prior to pricing (equal to €4.99). Following the completion of the capital increase, the 3,529,565 new shares will represent 10.5% of the issued share capital of the Company before the capital increase and 9.5% after the capital increase. The financing is expected to close on or about December 8, 2020, subject to the satisfaction of customary closing conditions. The impact of this share capital increase on (i) the stake held in the Company’s share capital by a shareholder holding 1%, and (ii) the share of equity (on a consolidated and per-share basis) as at June 30, 2020, in each case calculated on a non-diluted and fully diluted basis, i.e. taking into account the issuance of a maximum of 1,733,048 new shares upon (x) exercise of all outstanding warrants and stock options, and (y) the definitive acquisition of all free shares outstanding is as follows: Shareholder’s interestShare of equity (consolidated and per-share basis)Before issue of 3,529,565 new shares1.00%€2.85After issue of 3,529,565 new shares (non-diluted basis)0.90%€2.95After issue of 3,529,565 new shares and of 1,733,048 new shares resulting from outstanding dilutive instruments (fully diluted basis)*0.86%€3.08 *The shares issuable from the additional contingent consideration payable to Aciex’s former shareholders are not included in the above table as the Company considers it improbable that the conditions for the payment of this additional remuneration will be met. Directors and Executive Committee members of Nicox have agreed to certain customary lock-up arrangements with the Placement Agents on the shares they hold in Nicox for a 90-day period from the settlement date (subject to certain customary exemptions). Use of proceeds The net proceeds from the issuance of the new shares are intended for working capital purposes. Listing of new shares An application will be made for the admission to listing of the new shares on Euronext Paris. The settlement-delivery of the new shares is expected to take place on December 8, 2020. This financing does not require a listing prospectus submitted to the approval of the French Autorité des Marchés Financiers (AMF). Risks factors which are likely to have a material effect on Nicox’s business are presented (i) in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox’s website (www.nicox.com) and (ii) in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website. H.C. Wainwright & Co. and Bryan, Garnier & Co. are acting as joint lead placement agents for the financing. Composition of Nicox’s Share Capital The table below reflects the positions to the best of the Company’s knowledge. As of December 4, 2020 Number of shares and % of share capitalAfter share capital increase Number of shares and % of share capitalHBM Healthcare Investments2,383,808 / 7.12%2,619,102 / 7.07%Orbimed1,608,553 / 4.80%1,608,553 / 4.34%Maven Investments Partners Limited- / 0%800,000 / 2.16%Banque Publique d'Investissement384,300 / 1.15%384,300 / 1.04%Michele Garufi567,051 / 1.69%567,051 / 1.53%Elizabeth Robinson74,060 / 0.22%74,060 / 0.20%Public28,473,598 / 85.02%31,352,169 / 84.69%Total33,491,370 / 100%37,020,935 / 100% HBM Healthcare Investments, which held 2,383,808 shares as of December 4, 2020, representing 7.12% of the share capital, subscribed 235,294 shares as part of this transaction. About Nicox Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com. Analyst coverage Bryan, Garnier & Co Victor Floc’h Paris, FranceCantor Fitzgerald Louise Chen New York, U.S.H.C. Wainwright & Co Yi Chen New York, U.S.Kepler Cheuvreux Damien Choplain Paris, FranceOppenheimer & Co Hartaj Singh New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 firstname.lastname@example.org Investors & MediaUnited States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 email@example.comMediaFranceLifeSci Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 firstname.lastname@example.org Forward-Looking Statements The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented (i) in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox’s website (www.nicox.com) and (ii) in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website.. Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 Forward-Looking Statements This announcement is for information purposes only and does not, and shall not, in any circumstances, constitute a public offering by Nicox, nor a solicitation of an offer to subscribe for securities in any jurisdiction, including France. The securities referred to herein (the "Shares") may not be and will not be offered or sold to the public in France except to qualified investors and/or to a restricted circle of investors, acting for their own account, as defined in, and in accordance with the applicable provisions of the Prospectus Regulation and the French Monetary and Financial Code. In each of the various Member States of the European Economic Area, including France, and the United Kingdom (the “Relevant States”), no action has been undertaken or will be undertaken to make an offer to the public of the Shares requiring the publication of a prospectus in any Relevant State. Consequently, the securities cannot be offered and will not be offered in any Relevant State, except in accordance with the exemptions set forth in Article 1(4) of the Prospectus Regulation or in other cases which do not require the publication by Nicox of a prospectus pursuant to Article 3 of the Prospectus Regulation and/or applicable regulations in the Relevant States. For the purposes of this paragraph, the expression “Prospectus Regulation” means Regulation (EU) 2017/1129 of the European Parliament and Council of 14 June 2017. This announcement and the information it contains do not constitute an offer of securities for sale nor a solicitation of an offer to purchase securities in the United States or in any other jurisdiction. The Shares may not be offered, sold or subscribed in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The shares of Nicox have not been and will not be registered under the U.S. Securities Act and Nicox does not intend to register any portion of the offering in the United States, or to conduct a public offering of its securities in the United States. The distribution of this press release has not been made, and has not been approved, by an “authorised person” within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. As a consequence, this press release is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents. The distribution of this announcement in certain countries may be subject to specific regulations. The persons in possession of this announcement shall then get knowledge of any local restrictions and shall comply with these restrictions. Any decision to subscribe for Shares should only be made on the basis of public information about Nicox. No copy of this announcement has been or should be distributed or sent to the United States of America, Canada, Japan or Australia." MiFID II Product Governance According to the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures, the target market assessment in respect of the offered Nicox shares (the "Offered Shares") has led to the conclusion that : (i) the target market of the Offered Shares is eligible counterparties, professional clients and retail clients, each as defined in MiFID II; and (ii) all channels for distribution of the Offered Shares are appropriate (the "Target Market Assessment"). Any person subsequently offering, selling or recommending the Offered Shares (a "distributor") should take into consideration the manufacturer’s Target Market Assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Offered shares (by either adopting or refining the manufacturer’s Target Market Assessment) and determining appropriate distribution channels. The Target Market Assessment is conducted solely for the purposes of the manufacturer’s product approval process and neither constitutes an assessment for any particular client of suitability or appropriateness for the purposes of MiFID II nor a recommendation to invest in, or purchase, or take any other action whatsoever with respect to the Offered Shares. Notwithstanding the Target Market Assessment, the attention of distributors is drawn to the fact that: the price of the Offered Shares may decline and investors could lose all or part of their investment; the Offered Shares offer no guaranteed income and no capital protection; and that an investment in the Offered Shares is compatible only with investors who do not need a guaranteed income or capital protection, who are capable (either alone or in conjunction with an appropriate financial or other adviser) of evaluating the merits and risks of such an investment and have sufficient resources to be able to bear any losses that may result therefrom. Attachment EN_PIPE 2020_20201204_VF
Investigations are continuing into the cause of an explosion at a waste water treatment works near Bristol which left four people dead. Three employees of Wessex Water and a contractor were killed in the blast at the firm's water recycling centre in Kings Weston Lane, Avonmouth, on Thursday. Prime Minister Boris Johnson said "our hearts go out" to the victims and their families, while Labour leader Sir Keir Starmer also offered his condolences.
Friday briefing: Crunch weekend in Brexit deal talksBill looms that would break withdrawal agreement … Biden: let’s all wear masks to kick off my presidency … Merkel heir-designate runs into trouble
Investors worried about whether a looming government shutdown could slow U.S. stocks' recent surge can take comfort in history: markets have tended to shrug off shutdowns despite their potentially nasty economic impact. Since 1984, the S&P 500 has averaged a 1.3% gain during government shutdowns, having edged lower in only two out of the last 10 instances. The most recent shutdown, which lasted for five weeks, shaved 0.1% and 0.2% from real U.S. gross domestic product in the fourth quarter of 2018 and the first quarter of 2019, respectively, according to the Congressional Budget Office.
The Queen's beloved dorgi Vulcan has died, according to reports. Of her famous and somewhat iconic dogs, the monarch now has only the ageing Candy remaining. News of Vulcan’s death comes days after the Duke and Duchess of Cambridge lost their nine-year-old dog Lupo.
Kane Williamson showed few signs he has not played a test since March as the New Zealand captain posted a career-best 251 on the second day of the opening test against West Indies in Hamilton on Friday. Williamson's 22nd test century, and third double ton, made up almost half of New Zealand's first innings total of 519 for seven declared before the tourists reached 49 without loss in reply. John Campbell was on 22 and Kraigg Brathwaite 20 not out at the close of play at Seddon Park.
A number of hand sanitisers have been found containing less alcohol than described via online marketplaces which could leave people unprotected against coronavirus. The worst offending product was identified as the Klenzy Hand Sanitizing Gel, available for sale on eBay, a Which? It claims to have a 75 per cent alcohol content but actually containing just 10 per cent, according to tests by the consumer group.
A bilateral trade deal between Taiwan and the United States would reinforce U.S. support for the democratic island in the face of "unrelenting intimidation" from China, Taiwan President Tsai Ing-wen said on Friday. Taiwan, claimed by China as its own territory, has long angled for a trade deal with its most important diplomatic and military backer, and in August Tsai announced a relaxation on imports of U.S. pork and beef, removing a stumbling block.
Japan's core machine orders likely rebounded in October along with demand for Japanese exports, a Reuters poll showed on Friday, but a resurgence in coronavirus cases at home and abroad could dampen the economic outlook. Core machinery orders, widely considered an indicator of capital spending in the next six to nine months, likely rose 2.8% in October from the previous month, when orders fell 4.4%, according to the poll of 18 economists. But the highly volatile data due on Wednesday is expected to show core orders, excluding those for ships and electrical utilities, likely dropped 11.3% in October from a year earlier after falling 11.5% year-on-year in September.
Between April and September, when India's economy was in a "technical recession," FDI into the country rose 15% despite coronavirus. Nearly 60% of this FDI came into India's computer software and hardware sectors.
Airlines eager to fill premium seats left empty by the coronavirus crisis are making a beeline for the entertainment and energy industries, which still must get its workers to far-off places. Most companies have slashed spending on corporate travel, leaving airlines without a crucial source of revenue. While travel groups expect new COVID-19 vaccines to help revive future business traffic, sectors like sporting events, streaming and content creation are a rare bright spot for airlines in the hard-hit travel sector.
British food banks are seeing more families needing their support as the impact of the COVID-19 pandemic forces struggling people to seek help, charities and volunteers say. The rise in those out of work has resulted in more people turning to food banks, which provide emergency food supplies to families in need. "I was working part-time as a cleaner for evenings, and then when COVID started, we had to quit because everything was closed and our offices, they're not opening until 2021 because people can work from home," said Vilma Tunylaite, 40, queuing at a food bank in southwest London.
On Thursday night, The Daily Show host Trevor Noah took aim at an unlikely target: Democratic politicians.You see, a number of Dem politicians of late have been caught telling their constituents to stay inside and avoid large gatherings while ignoring those rules themselves. Among the offending Dems were San Francisco Mayor London Breed, who attended a group dinner at the swanky restaurant French Laundry; California Governor Gavin Newsom, who was among a group of 12 people dining at French Laundry; and Austin Mayor Steve Adler, who made a video cautioning his fellow Austinites to “stay inside”—but recorded it from a vacation timeshare in Cabo San Lucas, Mexico.“Oh man, come on! What is it with these Democrats?” asked Noah, before mimicking Adler’s message to the public: “This is your mayor here, telling you to stay home, and stay safe. Do the right thing… All my boys in the pool know what I’m talking about! Say what’s up, everybody!”“I’m sorry, man. Everyone has given up their lives and then you’ve got these politicians who are just hypocrites out here?” he continued. “What, you guys think corona respects your office too much to come after you? Because don’t forget: it got the president of the United States, it’s not going to be star-struck by Governor Hair Gel,” he cracked, throwing to a photo of Gavin Newsom.Kevin Sorbo Was Hercules. Now He Trolls Liberals All Day on Twitter.The comedian said that even though Republicans are going maskless in droves, and the Trump administration is going so far as to throw a series of indoor parties at the White House—despite a number of Trump administration members contracting COVID—he’s more disappointed in the Dem politicians due to their “hypocrisy.”“In a way, these Democrats are even worse than the anti-maskers because of their hypocrisy,” said Noah. “At least when those dudes break the rules they’re open about it.”Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
Police say the explosion at a water recycling centre in Avonmouth happened in a biosolid treatment silo, though the cause of the blast is unknown.
A chilly breeze whirls through New Delhi in the mornings and the sun is partly obscured by toxic haze, a marker of another winter in the Indian capital. The perpetually busy arterial highways that connect most northern Indian towns to this city of 29 million people now pulse to the cries of “Inquilab Zindabad” — “Long live the revolution.” Tens and thousands of farmers with distinctive, colorful turbans and long, flowing beards have descended upon the city's borders, choking highways in giant demonstrations against new farming laws that they say will open them to corporate exploitation.
Celebrities and opposition MPs have lobbied against the deportation of 36 jail prisoners to Jamaica.
Going wild? A radical green plan for Nottingham's unloved shopping centre. Could replacing empty shops with wetlands, woodlands and meadows offer a new model for cities?